Document and Entity Information |
Jun. 12, 2026 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Document Period End Date | Jun. 12, 2026 |
| Entity Registrant Name | biote Corp. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40128 |
| Entity Tax Identification Number | 85-1791125 |
| Entity Address Address Line 1 | 1875 W. Walnut Hill Ln #100 |
| Entity Address City Or Town | Irving |
| Entity Address State Or Province | TX |
| Entity Address Postal Zip Code | 75038 |
| City Area Code | 844 |
| Local Phone Number | 604-1246 |
| Security 12b Title | Class A common stock, par value $0.0001 per share |
| Trading Symbol | BTMD |
| Security Exchange Name | NASDAQ |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Entity Ex Transition Period | false |
| Amendment Description | This Amendment No. 1 on Form 8-K/A is an amendment to the current report on Form 8-K of biote Corp. (the “Company”), filed on June 2, 2026 (the “Original Form 8-K”). As disclosed on the Original Form 8-K, the board of directors of the Company (the “Board”) appointed Robert Peterson, Chief Financial Officer and Chief Business Officer of BioTE Medical LLC (“BioTE”), as Interim Chief Executive Officer of BioTE, effective June 8, 2026. At the time of his appointment, the Board had not yet approved any compensatory agreements for Mr. Peterson in his new role.On June 12, 2026, the Board approved and entered into an amended and restated employment agreement with Mr. Peterson. The Company is amending the Original Form 8-K to provide a description of the compensation arrangements and agreements for Mr. Peterson established in connection with his appointment as Interim Chief Executive Officer. |
| Entity Central Index Key | 0001819253 |
| Pre Commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | true |